Garnier, J.L., Chevallier, P., Dubernard, J.M., Trepo, C., Touraine, J.L. and Chossegros, P. (1997) Treatment of Hepatitis C Virus Infection with Ribavirin in Kidney Transplant Patients. Transplantation Proceedings, 29, 783.
https://doi.org/10.1016/S0041-1345(96)00100-5

has been cited by the following article:

• TITLE: Post Hepatitis C Cirrhosis in Sub-Sahara Kidney Transplant, Treated with Sofosbuvir/Ledipasvir: Report of Case and Review of Literature

  AUTHORS: Tsevi Yawovi Mawufemo, Lagou Amélie Delphine, Tia Weu Mélanie, Coulibaly Pessa Nawo Albert, Cherif Ibrahima, Guei Monlet Cyr, Ackoundou-N’Guessan Kan Clément

  KEYWORDS: Côte D’Ivoire, Direct-Acting Antivirals, Kidney Transplantation, Viral Hepatitis C

  JOURNAL NAME: Open Journal of Nephrology, Vol.7 No.4, December 22, 2017

  ABSTRACT: Background: Viral hepatitis C is a major public health problem in the world. The advent of direct-acting antivirals has revolutionized the taking in charge and prognosis of patients infected with the hepatitis C virus. The interest of this presentation is to draw attention to the problem of therapeutic care posed by viral hepatitis C in kidney transplant patients in C?te d’Ivoire, a country with limited resources where all direct-acting antivirals are not yet available. Patient observation: We report the case of a kidney transplant of 52 years old, chronic bearer of viral hepatitis C virus who after his kidney transplant presented, decompensated active cirrhosis. A treatment based on Sofosbuvir 400 mg/Ledipasvir 90 mg in this patient with genotype 2 for 12 weeks was initiated. A sustained virological response was observed 12 weeks after the end of treatment. Conclusion: Direct-acting antivirals offer the possibility of antiviral C treatment without interferon or ribavirin in cirrhotic renal transplant.